LifeStance Health Group Financial Statements (LFST) |
||||||||||
LifeStance Health Groupsmart-lab.ru | % | 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
---|---|---|---|---|---|---|---|---|---|---|
Report date | 31.12.2020 | 17.03.2022 | 31.12.2022 | 09.03.2023 | 31.12.2023 | 07.11.2024 | ||||
Currency | USD | USD | USD | USD | USD | USD | ||||
Financial report URL | ||||||||||
Revenue, bln rub | ? | 377.2 | 667.5 | 859.5 | 859.5 | 1 056 | 1 206 | |||
Operating Income, bln rub | 15.4 | -286.4 | -210.2 | -210.2 | -189.1 | -63.5 | ||||
EBITDA, bln rub | ? | 8.77 | -229.6 | -109.3 | -136.4 | -104.9 | 14.1 | |||
Net profit, bln rub | ? | -38.1 | -307.2 | -215.6 | -215.6 | -186.3 | -95.3 | |||
OCF, bln rub | ? | -8.53 | 9.42 | 52.8 | 52.8 | -16.9 | 61.7 | |||
CAPEX, bln rub | ? | 38.1 | 94.5 | 79.3 | 79.3 | 40.5 | 26.7 | |||
FCF, bln rub | ? | -46.6 | -85.1 | -26.5 | -26.5 | -57.4 | 35.1 | |||
Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |||||
Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
OPEX, bln rub | 330.7 | 487.9 | 1 070 | 447.2 | 491.2 | 588.7 | ||||
Cost of production, bln rub | 242.9 | 466.0 | 0.000 | 622.5 | 753.6 | 1 142 | ||||
R&D, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
Interest expenses, bln rub | 22.1 | 38.9 | 19.9 | 19.9 | 21.2 | 22.7 | ||||
Assets, bln rub | 1 570 | 1 927 | 2 174 | 2 174 | 2 233 | 2 108 | ||||
Net Assets, bln rub | ? | 997.8 | 1 545 | 1 519 | 1 519 | 1 429 | 1 437 | |||
Debt, bln rub | 362.5 | 157.4 | 476.5 | 476.5 | 511.0 | 486.7 | ||||
Cash, bln rub | 18.8 | 148.0 | 108.6 | 108.6 | 78.8 | 102.6 | ||||
Net debt, bln rub | 343.7 | 9.39 | 367.9 | 367.9 | 432.2 | 384.1 | ||||
Ordinary share price, rub | 9.52 | 4.94 | 4.94 | 7.83 | 5.95 | |||||
Number of ordinary shares, mln | 373.6 | 327.5 | 355.3 | 355.3 | 367.5 | 378.7 | ||||
Market cap, bln rub | 0 | 3 118 | 1 755 | 1 755 | 2 877 | 2 253 | ||||
EV, bln rub | ? | 344 | 3 127 | 2 123 | 2 123 | 3 309 | 2 637 | |||
Book value, bln rub | -434 | 40 | -18 | -18 | -85 | -52 | ||||
EPS, rub | ? | -0.10 | -0.94 | -0.61 | -0.61 | -0.51 | -0.25 | |||
FCF/share, rub | -0.12 | -0.26 | -0.07 | -0.07 | -0.16 | 0.09 | ||||
BV/share, rub | -1.16 | 0.12 | -0.05 | -0.05 | -0.23 | -0.14 | ||||
EBITDA margin, % | ? | 2.32% | -34.4% | -12.7% | -15.9% | -9.94% | 1.17% | |||
Net margin, % | ? | -10.1% | -46.0% | -25.1% | -25.1% | -17.6% | -7.90% | |||
FCF yield, % | ? | -2.73% | -1.51% | -1.51% | -2.00% | 1.56% | ||||
ROE, % | ? | -3.82% | -19.9% | -14.2% | -14.2% | -13.0% | -6.63% | |||
ROA, % | ? | -2.43% | -15.9% | -9.92% | -9.92% | -8.34% | -4.52% | |||
P/E | ? | 0.00 | -10.1 | -8.14 | -8.14 | -15.4 | -23.6 | |||
P/FCF | 0.00 | -36.7 | -66.3 | -66.3 | -50.1 | 64.3 | ||||
P/S | ? | 0.00 | 4.67 | 2.04 | 2.04 | 2.73 | 1.87 | |||
P/BV | ? | 0.00 | 77.7 | -100.2 | -100.2 | -33.7 | -43.7 | |||
EV/EBITDA | ? | 39.2 | -13.6 | -19.4 | -15.6 | -31.5 | 186.9 | |||
Debt/EBITDA | 39.2 | -0.04 | -3.37 | -2.70 | -4.12 | 27.2 | ||||
R&D/CAPEX, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
CAPEX/Revenue, % | 10.1% | 14.2% | 9.22% | 9.22% | 3.84% | 2.21% | ||||
LifeStance Health Group shareholders |